Company Description
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases.
The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.
Renovaro Inc. is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David Weinstein |
Contact Details
Address: 2080 Century Park East, Suite 906 Los Angeles, California 90067 United States | |
| Phone | 305 918 1980 |
| Website | renovarogroup.com |
Stock Details
| Ticker Symbol | RENB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001527728 |
| CUSIP Number | 29350E104 |
| ISIN Number | US29350E1047 |
| Employer ID | 45-2259340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David H. Weinstein | Chief Executive Officer and Director |
| Nathen Fuentes CPA | Chief Financial Officer |
| Greg Duczynski Ph.D. | Senior Vice President for Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 25, 2025 | 8-K | Current Report |
| Jul 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 10, 2025 | SCHEDULE 13D/A | Filing |
| Jul 9, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 14, 2025 | SCHEDULE 13D/A | Filing |
| Apr 10, 2025 | 8-K | Current Report |